BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37538807)

  • 1. Relationship between the Gene Expression of Adenosine Kinase Isoforms and the Expression of CD39 and CD73 Ectonucleotidases in Colorectal Cancer.
    Zhulai GA; Shibaev MI
    Acta Naturae; 2023; 15(2):42-49. PubMed ID: 37538807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ADK-S and ADK-L Isoforms and Their Association with CD39/CD73/A2aR in Colorectal Cancer.
    Zhulai GA; Shibaev MI
    Bull Exp Biol Med; 2023 Nov; 176(1):91-95. PubMed ID: 38085399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenosine Generated by Regulatory T Cells Induces CD8
    Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
    Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The abnormal function of CD39
    Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
    Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
    Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
    Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer.
    Zhulai G; Oleinik E; Shibaev M; Ignatev K
    Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
    Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
    Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
    Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
    Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
    Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
    Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
    Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
    J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.
    Zacca ER; Amezcua Vesely MC; Ferrero PV; Acosta CDV; Ponce NE; Bossio SN; Mussano E; Onetti L; Cadile I; Acosta Rodríguez EV; Montes CL; Gruppi A
    J Mol Biol; 2021 Jan; 433(1):166687. PubMed ID: 33098857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
    Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
    Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1.
    de Lourdes Mora-García M; López-Cisneros S; Gutiérrez-Serrano V; García-Rocha R; Weiss-Steider B; Hernández-Montes J; Sánchez-Peña HI; Ávila-Ibarra LR; Don-López CA; Muñóz-Godínez R; Pineda DBT; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
    Mediators Inflamm; 2019; 2019():4651627. PubMed ID: 31205451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.
    Muñóz-Godínez R; de Lourdes Mora-García M; Weiss-Steider B; Montesinos-Montesinos JJ; Del Carmen Aguilar-Lemarroy A; García-Rocha R; Hernández-Montes J; Azucena Don-López C; Ávila-Ibarra LR; Torres-Pineda DB; Molina-Castillo G; Chacón-Salinas R; Vallejo-Castillo L; Pérez-Tapia SM; Monroy-García A
    Mediators Inflamm; 2020; 2020():1678780. PubMed ID: 33488292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
    Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
    Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.